Mitsubishi UFJ Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.6K	Hold	586	–	–	﹤0.01%	1148
2026 Q1	$43.5K	Hold	586	–	–	﹤0.01%	1071
2025 Q4	$45.8K	Hold	586	–	–	﹤0.01%	1076
2025 Q3	$30.4K	Hold	586	–	–	﹤0.01%	1092
2025 Q2	$25.3K	Buy	+586	New	+$21.3K	﹤0.01%	1128
2024 Q2	–	Sell	-5,845	Closed	-$181K	–	1574
2024 Q1	$181K	Sell	5,845 -268	-4%	-$9.11K	﹤0.01%	970
2023 Q4	$231K	Sell	6,113 -9,176	-60%	-$276K	﹤0.01%	994
2023 Q3	$403K	Buy	15,289 +720	+5%	+$20.4K	﹤0.01%	949
2023 Q2	$251K	Sell	14,569 -6,474	-31%	-$97.4K	﹤0.01%	1009
2023 Q1	$349K	Buy	21,043 +1,699	+9%	+$19.8K	﹤0.01%	968
2022 Q4	$139K	Sell	19,344 -5,534	-22%	-$53K	﹤0.01%	1061
2022 Q3	$247K	Buy	24,878 +1,613	+7%	+$16.8K	﹤0.01%	1001
2022 Q2	$211K	Buy	+23,265	New	+$195K	﹤0.01%	1038

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Mitsubishi UFJ Asset Management's BBIO Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 586 shares worth $43.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1148.

Mitsubishi UFJ Asset Management first reported a position in BBIO in Q2 2022 and has held it in 13 quarters since. The position peaked at $403K in Q3 2023. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Mitsubishi UFJ Asset Management held 586 shares of BridgeBio Pharma worth $43.6K as of Q2 2026.
Mitsubishi UFJ Asset Management left its BridgeBio Pharma share count unchanged in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #1148 holding.
Mitsubishi UFJ Asset Management first reported a position in BridgeBio Pharma in Q2 2022 and has held it in 13 quarters since.
Mitsubishi UFJ Asset Management's BridgeBio Pharma position peaked at $403K in Q3 2023.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.